Skip to main content

This job has expired

You will need to login before you can apply for a job.

Associate Scientist II, Drug Product Analytics

Vaxcyte, Inc.
San Carlos, California
Start date
Feb 9, 2024

View more

Marketing, Science/R&D, Biotechnology, Pharmacology
Required Education
Bachelors Degree
Position Type
Full time
Biotech Bay

Job Details

Company Profile:
Vaxcyte, Inc. (Nasdaq: PCVX) is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). The Company is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and our exclusively licensed XpressCFTM cell-free protein synthesis platform. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine program designed to prevent Shigella. The Company is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit
Vaxcyte, headquartered in San Carlos, CA, went public in June 2020 and currently has a team of approximately 180 employees and anticipates continued, significant growth. Following equity offerings in October 2022 and April 2023, which generated over $1.1 billion in net proceeds, the Company’s balance sheet is further strengthened to advance its pipeline of novel vaccines, including VAX-24. These financings followed positive data readouts from Vaxcyte’s Phase 1/2 proof-of-concept study evaluating VAX-24 in adults aged 18-64 and Phase 2 study in adults 65 and older. The Company believes these results support a best-in-class potential for VAX-24, which was designed to replace the current standard-of-care in adults and children. VAX-24 is being investigated for the prevention of IPD, which can be most serious for infants, young children, older adults and those with immune deficiencies or certain chronic health conditions. Given the global impact of pneumococcal disease remains significant, the public health community continues to advocate for vaccines that can offer broader protection to prevent IPD. Vaxcyte’s PCV franchise, consisting of VAX-24 and VAX-31, is designed specifically to address this need and has the potential to deliver the broadest protection for this very serious disease. We believe that our PCVs could receive regulatory approval based on successful completion of clinical studies utilizing well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies.
Vaxcyte is looking for an energetic and talented individual to join our Drug Product Analytics team. Vaxcyte has relocated to San Carlos in late 2021, into custom designed, state of the art laboratories and working environment.
The candidate will have knowledge and practical experience in analyzing and characterizing large biomolecules and biological Drug Products. The responsibilities will be primarily to perform routine testing in support of formulation development and to develop analytical methods (e.g., HPLC, particle analytics) under supervision. This position is to support the formulation team across all projects in the pipeline in all stages of development.
The candidate will work under supervision to develop analytical methods, perform analytical data review and, support assay transfer activities with the Vaxcyte QC team and external CMO partner groups.
Essential Functions:
    • Routine analysis of internal stability samples and reporting of data using HPLC, spectroscopy, immunoassay and physical analytical methodologies.
    • Support in depth characterization of the Drug Product Under direct supervision, evaluate and develop the most appropriate biophysical characterization tools to support adjuvanted vaccine Drug Products.
    • Support the Vaxcyte QC team, external analytical and manufacturing CMOs to enable tech transfer and implementation of processes and analytical methods.
    • Vaxcyte is looking for an experienced and flexible individual who would be comfortable working on multiple projects at once, with fluid prioritization to enable aggressive timelines. This position is for a scientific role, which is predominantly lab based, requiring excellent scientific judgement, independence, rigor and thorough record keeping.

    • BSc or MSc in, Chemistry, Biochemistry, Biophysics or Pharmaceutics preferred, with >1 years of industrial experience. 
    • The candidate will preferably have some experience in characterization of large biomolecules and/or Drug Products.
    • Some experience in spectrometric methodologies (UV-Vis, Fluorescence), plate-based assays, immunoassay/ELISA, HPLC/UV, SEC/MALS and particle light scattering analysis, is advantageous. 
    • Experience in authoring analytical technical documents, including method protocols and SOPs, assay transfer and implementation protocols and reports is beneficial. 
    • Strong interpersonal skills: ability to communicate effectively both verbally and in written formats are necessary to collaborate effectively with the rest of the Formulation and Drug Product Development team and well as across other teams.
    • Detail oriented, rigorous and excellent skills in record keeping/
    • All Vaxcyte employees require vaccination against COVID-19.

Reports to: Group Leader, Drug Product Analytics
Location: San Carlos, CA
The compensation package will be competitive and includes comprehensive benefits and an equity component.
Salary Range: $101,000 – $112,000


Vaxcyte, Inc. (Nasdaq: PCVX) is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent some of the most common and deadly infectious diseases worldwide. Our exclusively licensed cell-free protein synthesis platform and our proprietary know how enable us to design and produce optimized protein carriers and antigens, the critical building blocks of vaccines, in ways that we believe conventional vaccine technologies cannot. Our lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Our pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of at least 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease by targeting the keystone pathogen responsible for this chronic, oral inflammatory disease.

Company info
(650) 837-0111
825 Industrial Road, Suite 300
San Carlos

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert